摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,3-二氢异苯并呋喃-5-硼酸频哪醇酯 | 1352037-60-5

中文名称
1,3-二氢异苯并呋喃-5-硼酸频哪醇酯
中文别名
——
英文名称
2-(1,3-dihydroisobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
英文别名
2-(1,3-dihydro-2-benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
1,3-二氢异苯并呋喃-5-硼酸频哪醇酯化学式
CAS
1352037-60-5
化学式
C14H19BO3
mdl
——
分子量
246.114
InChiKey
JHDYIHQRIANGLR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.02
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    27.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
    申请人:Dow AgroSciences LLC
    公开号:US09149038B2
    公开(公告)日:2015-10-06
    Novel 4-amino-6-(heterocyclic)picolinic acids and their derivatives and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their derivatives are useful to control undesirable vegetation.
    新型的4-基-6-(杂环)吡啶酸及其衍生物和6-基-2-(杂环)嘧啶-4-羧酸酯及其衍生物可用于控制不良植被。
  • EP3187498
    申请人:——
    公开号:——
    公开(公告)日:——
  • US2014/274701
    申请人:——
    公开号:——
    公开(公告)日:——
  • US20140274701A1
    申请人:——
    公开号:——
    公开(公告)日:——
  • SELECTIVE BET INHIBITORS AND USES THEREOF
    申请人:[en]TAY THERAPEUTICS LIMITED
    公开号:WO2024138201A2
    公开(公告)日:2024-06-27
    This disclosure relates to certain pyrrolopyridone compounds. Certain compounds of the disclosure are potent and selective Bromodomain and Extra-Terminal (BET) inhibitors. The disclosure also relates to pharmaceutically acceptable salts of the compounds or N-oxides thereof, methods of treating diseases and disorders using the compounds, salts, or N-oxides thereof and compositions comprising the compounds salts or N-oxides thereof. The disclosure additionally relates to methods for the treatment of inflammatory and autoimmune diseases and disorders (e.g., skin diseases and disorders, joint and joint-related diseases and disorders, and fibrosis or fibrosis-associated diseases or disorders) using potent and selective BET inhibitors and formulations comprising the disclosed BET inhibitors.
查看更多